Nectin Therapeutics is a clinical stage biotechnology company devoted to transforming the lives of cancer patients by leveraging unique insights into nectin pathways to develop the next generation of immune oncology (IO) therapies. The company's differentiated therapies have the potential to set new standards for efficacy and patient response rates across various difficult-to-treat cancers. Nectin's technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody drug conjugates (ADCs). It has a world-class scientific and management team with deep experience in oncology drug development and successful track records in building biotechnology companies and developing innovative therapies. Founded by Dr. Pini Tsukerman, Prof Ofer Mandelboim (HUJI) and Prof Stipan Jonjic (MEDRI), Nectin Therapeutics is a venture-backed, privately held company, funded by aMoon Fund, Peregrine Ventures, IBF, Integra Holdings, the Myeloma Investment Fund and the Cancer Focus Fund.
Fabian Tenenbaum (M.BA) CEO
Keren Paz (Ph.D.) CDO
Pini Tsukerman (Ph.D.) CSO
Guy Cinamon (Ph.D.) VP R&D
Anas Atieh (M.Sc) Lab Head
Akram Obeidat (Ph.D.) Senior Scientist
Alon Vitenstein (Ph.D.) Senior Scientist
Rivki Cashman (Ph.D.) Senior Scientist
Simona Chechik (M.Sc.) Scientist
Orr Ben-Shaul (M.A) Administrative manager